1. Home
  2. Research
  3. Research Groups
  4. Molecular Pathology of Cancer Group

Molecular Pathology of Cancer Group

Search for publications

Only original articles, editorials, guidelines.

  • Garcia-Prieto CA, Musulen E, Grases D, Davalos V, Ferrer G, Pérez-Miés B, Caniego-Casas T, Palacios J, Saenz-Sardà X, Englund E, Porta E, Esteller M.

    Spatial transcriptomics unveils the in situ cellular and molecular hallmarks of the lung in fatal COVID-19.

    Nature Communications . 17(1): .

    [doi:10.1038/s41467-026-78188-3]

  • Urun Y, Sridharan K, Zgura A, Zayed A, Laguado MIZ, Yetisyigit T, Yano A, Wenzel M, Vau N, Tural D, Trindade K, Tran B, Ting FIL, Templeton AJ, Takeshita H, Sunela K, Souza VC, Sooro MA, Soares A, Siva S, Singh A, Silveira G, Shah S, Seront E, Schutz FA, Schurmann MLV, Schieber T, Scagliarini S, Sargsyan A, Simonetti CS, Rushanyan M, Roviello G, Rodriguez-Vida A, Rodriguez Gonzalez OE, Roberts R, Van der Veldt AAM, Rizzo M, Rizzo A, Poprach A, Pirshtuk A, Pinto A, Pierce E, Peñaloza JM, Pedrani M, Park SH, Okunade IA, Odounga KF, Noriega J, Noorzai E, Coronel MTN, Navratil J, Myint ZW, Mutavdzic V, Mukuku O, Mugarura R, Marques Monteiro FS, Mohamed AH, Mmereki D, Messina C, Melichar B, Mukaz Mbey P, Maturana E, Matthews D, Massari F, Martínez E, Maitre P, Maison P, Ndjembidouma BCM, Lu K, Li J, Li H, de Moura Leite L, Lalani AA, Küronya Z, Kucharz J, Koumba AB, Kopp RM, Kopecky J, Kihn-Alarcón AJ, Keskin Ö, Kabdullina K, Juarez Á, Fita MJJ, Jardim DL, James LG, Grande E, De Liaño AG, Giannatempo P, Ghosn M, Gauna C, Quiroga MNG, Fujita K, Pereira Freitas MR, Fiala O, Lazzaro MF, Pacheco GMF, Esan TO, Esan DT, Du Plessis D, Delgado SN, Crabb SJ, Cano RC, Corrales L, Chen J, Cayol F, Silva CC, Carneiro APCD, Caprinciu GA, Campos S, Büttner T, Buti S, Bukhari N, Buchler T, Bourlon MT, Bolek H, Boegemann M, Bilen MA, Vaca LB, Bastos DA, Barthelemy P, Bardakhchyan S, Barbu MA, Baranseh J, Bamias A, Bakenga A, Anguera G, Angel M, Silva CAC, Alonso-Gordoa T, Almugbel F, Almufti R, Almeida TL, Aliyev A, Aliaga C, Aleem U, Akkus E, Aceituno LG, Abidi SH, Abahssain H, Tartari F, Molina-Cerrillo J, Santoni M.

    Global disparities in the availability and reimbursement of systemic therapies for renal cell carcinoma: results of the International ARON-AID Survey.

    ONCOLOGIST . 31(11): .

    [doi:10.1093/oncolo/oyag397]

  • Velasco G, Alonso-Gordoa T, Rodríguez-Moreno JF, Duran I, Carril Ajuria L, Álvarez Ballesteros P, González-Billalabeitia E, Domínguez JI, García-Casas A, Pérez-Navarro E, Sánchez-Redondo S, Molina-Cerrillo J, Guerrero-Ramos F, Manneh Kopp R, Marinas C, Paramio JM, Peinado H, Castellano D, Dueñas M.

    CABOPRE: Evaluating Perioperative Cabozantinib's Efficacy and Biomarkers for Cytoreductive Nephrectomy in Advanced Renal Cell Carcinoma.

    Cancers . 18(19): .

    [doi:10.3390/cancers18193216]

  • Wenham RM, Ray-Coquard I, Kristeleit R, Matei D, Ghamande S, Oaknin A, Berek JS, Perez-Fidalgo JA, Sentís PG, Guerra Alia EM, Hou J, Follana P, Eberst L, Clamp A, Frenel JS, Roxburgh P, Jones RH, Pautier P, Jackson AL, Armstrong DK, Song T, Nomoto M, Hawk N, Scott R, Makker V.

    Farletuzumab ecteribulin, a folate receptor alpha (FRa) antibody-drug conjugate, in select advanced cancers: An open-label, multicenter, phase 1/2 dose-finding study.

    Gynecologic Oncology . 213: 109-119.

    [doi:10.1016/j.ygyno.2026.08.023]

  • Pernas S, Forns X, Martínez-Sáez O, Andrade R, Amador A, López-Miranda E, Bermejo B, Mateos B, Cejuela M, Villanueva MJ, Ozores PP, Riveiro-Barciela M, Bellet M.

    Expert consensus on optimal management of liver-related adverse events during CDK4/6 inhibitor therapy.

    Clinical & Translational Oncology . 28(10): 4546-4559.

    [doi:10.1007/s12094-026-04369-7]

  • Matheu G, Bermejo-Peréz MJ, Escudero-García N, Garcia-Duran C, Gatius-Caldero S, Guerra-Alía E, López-Agullo S, Romero I, Yange G, Barretina-Ginesta MP.

    Morphological and molecular characterization of epithelial ovarian cancer: SEOM-SEAP consensus guidelines for biomarker integration in clinical practice.

    Clinical & Translational Oncology . 28(10): 4359-4375.

    [doi:10.1007/s12094-026-04335-3]

  • Garcia-Carbonero R, Cote GM, Le Cesne A, Antón-Pascual B, Alonso-Gordoa T, Falcon A, Gil-Torralvo A, Martínez S, Kahatt C, Alfaro V, Zubiaur P, Jimenez J, Siguero M, Molina-Cerrillo J.

    Lurbinectedin plus irinotecan in pretreated gastroenteropancreatic neuroendocrine neoplasms: results of a phase II expansion cohort.

    ESMO Open . 11(10): 108534-108534.

    [doi:10.1016/j.esmoop.2026.108534]

  • Garcia-Regal C, Quiñones-Silva J, Brox-Torrecilla N, Martinez-Lorca A, Ruz-Caracuel I, Arias HP, Manso SA, Garcia Cano AM, Rosillo M, Luengo P, Guerrero BP, García Gómez Muriel MI, Casado CF, Pamplona Civera MJ, Lázaro VA, Paja M, Guijarro de Armas MG, Bolaños PI, Valderrabano P.

    Outcomes of patients with low-risk differentiated thyroid cancer with an excellent response to initial therapy.

    European Thyroid Journal . 15(5): .

    [doi:10.1530/ETJ-26-0223]

  • Sridharan K, Alonso-Gordoa T, Sivaramakrishnan G, Cerrillo JM, Fiala O, Rehan F, Mena Cortes D, Santoni M.

    Theranostics in the management of prostate cancer: from concept to clinical practice.

    Expert Review of Clinical Pharmacology . 19(9): 837-854.

    [doi:10.1080/17512433.2026.2737765]

  • Borque-Fernando Á, Alonso-Gordoa T, Juan-Fita MJ, Lopez Campos F, Pérez-Fentes DA, Vilaseca A, Moretones Agut C, Usán P, Maroto Rey P.

    Multidisciplinary expert consensus on treatment intensification in metastatic androgen pathway modulation-sensitive prostate cancer: a case-based RAND/UCLA analysis.

    Drugs in Context . 15: .

    [doi:10.7573/dic.2026-6-2]

  • Martín M, Rodriguez-Lescure A, Reboredo C, Chen E, Ruiz-Borrego M, Santaballa Bertran A, Rodríguez CA, Martinez Jañez N, Alba E, Tran K, Pelaez Fernandez I, Álvarez I, Seguí MA, De la Cruz A, Valero V, Antón-Torres A, Andrés R, Amillano K, Ponce-Lorenzo JJ, Dominguez Fernandez S, Herranz J, Rincon R, Caballero R, Guerrero-Zotano A, Rojo F, Symmans WF.

    Sensitivity to endocrine therapy index predicts benefit from weekly adjuvant paclitaxel for hormone receptor-positive breast cancer in the GEICAM/9906 trial.

    CLINICAL CANCER RESEARCH . 32(17): 3870-3879.

    [doi:10.1158/1078-0432.CCR-26-0177]

  • Molina-Cerrillo J, Alonso-Gordoa T.

    Re: Bevacizumab and Erlotinib in Hereditary and Sporadic Papillary Kidney Cancer.

    EUROPEAN UROLOGY . 90(3): 304-305.

    [doi:10.1016/j.eururo.2026.04.007]

  • Ariño-Palao C, Carretero-Barrio I, Martos-Meléndez S, Caniego-Casas T, Rosas M, Martínez-Jañez N, Fernández-Abad M, Sánchez MC, Presa-Abos T, Zamora J, Martínez-Aedo Castro J, Ledesma-Carbayo MJ, Palacios J, Pérez-Mies B.

    Tumour-infiltrating lymphocytes differ across MammaPrint® classifications in breast cancer.

    ENDOCRINE-RELATED CANCER . 33(9): .

    [doi:10.1530/ERC-26-0116]

  • Lara González LE, Giudici F, Salgado R, Yan H, Rojo F, Comerma L, Wienert S, Palacios J, Kos Z, de Haas SL, Rodriguez-Lescure A, Viale G, Zheng Y, Gao D, Kiermaier A, Andre F, Loibl S, Piccart MJ, Gelber R, Cameron D, Krop IE, Savas P, Nielsen TO, Denkert C, Michiels S, Loi S.

    Manual, digital, and AI tumour-infiltrating lymphocyte scoring: a secondary analysis of the APHINITY randomised trial.

    LANCET ONCOLOGY . 27(9): 1168-1180.

    [doi:10.1016/S1470-2045(26)00247-0]

  • Büttner T, Rizzo M, Bernal Vaca L, Molina-Cerrillo J, Alonso-Gordoa T, Juárez A, Buchler T, Seront E, Kucharz J, Gandur Quiroga MN, Bourlon MT, Bögemann M, Kopecky J, Rescigno P, Fiala O, Rodriguez-Vida A, Myint ZW, Ürün Y, Scagliarini S, Poprach A, Matthews D, Li H, Rizzo A, Mosca A, Lenci E, Melichar B, Wenzel M, Mandell P, Massari F, Antonarakis ES, Santoni M.

    Enzalutamide in metastatic hormone-sensitive prostate cancer: results from the international, multicentre, real-world ARON-3 study.

    PROSTATE CANCER AND PROSTATIC DISEASES . 29(3): 588-594. Number of citations: 11

    [doi:10.1038/s41391-025-01067-3]

  • Blancas I, de la Peña MG, Abad MF, Novoa SA, Cebrián EA, Bayona RS, Adelantado EZ, Conejero RA, Del Barco Berrón S, Atienza M, Molero A, Díaz-Cerezo S, Pérez-Rambla C, Pérez-Sádaba FJ, Manso L.

    Clinical experience and satisfaction in patients with advanced breast cancer participating in the abemaciclib patient support program in Spain: a prospective observational study.

    Clinical & Translational Oncology . 28(9): 3862-3871.

    [doi:10.1007/s12094-026-04267-y]

  • Naharro-Rodríguez J, Berna-Rico E, Perna-Monroy C.

    Asymptomatic Reticulated Erythematous Patches on the Trunk.

    Actas Dermo-Sifiliograficas . 117(8): 104646-104646.

    [doi:10.1016/j.ad.2026.104646]

  • Garcia-Regal C, Quiñones-Silva J, Martinez-Lorca A, Brox-Torrecilla N, Campos Mena S, Alonso-Gordoa T, Gómez-Ramírez J, Valderrabano P.

    Determinants of physicians' risk-benefit perceptions of adjuvant radioactive iodine for differentiated thyroid cancer.

    ENDOCRINE . 91(1): .

    [doi:10.1007/s12020-026-04717-1]